Skip to main content
Signal8
Launch Terminal

Aclarion, Inc. (ACON)

Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.

Sector: Services-Medical Laboratories

Industry: Medical - Healthcare Information Services

Aclarion, Inc. logo

Aclarion, Inc.

NASDAQ:ACONHealthcare
-1.02%$1.95
AH$1.93-0.95%vs close
Mkt Cap$5.62M
Float2.88M
O/S2.88M
Vol
$ Vol
RVOL
Inst Own4.0%
SI0.8%
Earnings
Dilution
Aclarion, Inc. logoNASDAQ:ACON$1.95-1.02%
Pipeline2 lead-sponsored trials·1 active0 completed(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Observational
    Unknown status

    NOCISCAN-Lumbar Spine (LS) Clinical Evaluation Study

    NOCISCAN-LS Disc MR Spectroscopy

    Lumbar Disc Disease

    Enrollment
    240
    Start
    Apr 2023est.
    Primary Completion
    Sep 2024est.
    Completion
    Dec 2025est.
    NCT04015791
  • Observational
    Recruiting

    Examination of Nociscan Impact on Low Back Pain Surgical Outcomes

    Fusion or TDR determined by investigator.

    Low Back Pain

    Enrollment
    300
    Start
    Jun 2025
    Primary Completion
    Sep 2027est.
    Completion
    Dec 2027est.
    NCT06661850
Search ClinicalTrials.gov for “Aclarion”